[概述]TREATMENT

Chance of long term survival for patient with local advance disease is about 20%.Tumor response rate is approximately 80%in EGFR mutant comparing to about 10%to 20%in patients with wild-type EGFR . Recent comparative study of gefitinib versus docetaxel co ......

——《Essential Internal Medicine》

书名：《Essential Internal Medicine》

栏目：Essential Internal Medicine > PART 2 RESPIRATORY DISEASES > Chapter 7 Bronchogenic Carcinoma > NON-SMALL-CELL LUNG CANCER

作者：Joseph JY SUNG Ji-yao WANG T

参编：Guang，fengSHI，LawrenceKSWONG，Xiao，weiYAN，JulianaCNCHAN（陈重娥），FrancisKLCHAN（陈家亮）

页码：158-160

版本：1

出版社：人民卫生出版社

出版时间：2009-05-01

▲ [概述]ADENOCARCINOMA

▼ [治疗]（一）Ⅱa类